Kesimpta gains but Ocrevus still dominates MS sales

Kesimpta is the only other multiple sclerosis drug showing strong growth as Ocrevus continues to dominate the market.

Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQB:RHHBY) remained the top-selling MS drug in 1Q23, netting CHF1.6 billion ($1.8 billion) in the quarter. Across eight other branded therapies, seven had declining revenue quarter-over-quarter, including the entire MS franchise of Biogen Inc. (NASDAQ:BIIB). This week, CEO Chris Viehbacher took his first major steps in resizing Biogen’s cost base and decreasing pipeline risk...